Apollo Hospitals has announced plans to acquire a 31% stake in its wholly owned subsidiary Apollo Health and Lifestyle (AHLL) from International Finance Corporation (IFC) for ₹1,254 crore. This move will consolidate Apollo’s full ownership and control over AHLL.
Upon completion, AHLL will become a 99.42% subsidiary of Apollo, with the remaining 0.58% held under the employee stock option plan (ESOP). The transaction is expected to close by November 2025, subject to clearance from the Competition Commission of India (CCI).
In a regulatory filing, Apollo said the acquisition will enable tighter operational integration and improve efficiencies across its diagnostic and healthcare services.
“This acquisition is a decisive step that will allow for sharper capital allocation and a greater focus on select high-potential segments,”— said Suneeta Reddy, MD, Apollo Hospitals Enterprise.
In parallel, Apollo’s board has approved an investment of ₹573 crore to establish a comprehensive oncology centre in Gurugram.
The facility will include a next-generation single gantry Proteus One Proton Beam Therapy system, with capacity to treat an additional 350 patients annually.
This new centre will be part of Apollo’s Phase 2 expansion at Gurugram, following its first phase of development.
Phase 1 is expected to be commissioned by end Q4FY25 or Q1FY26
The Proton & Integrated Cancer Centre will follow within the next four years
Apollo aims to double the scale of its oncology business to over ₹5,000 crore in 3–4 years, driven by high-end personalised care, precision medicine, and expanded presence in major metros and other cities.